Hepatitis C Virus NS5A Inhibitor [EPC]

This page covers all Hepatitis C Virus NS5A Inhibitor [EPC] drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Potassium voltage-gated channel subfamily H member 2.

Targets

Potassium voltage-gated channel subfamily H member 2

Marketed (5)

• Mavyret · AbbVie · Oncology
  Mavyret works by blocking the NS3/4A protease enzyme, preventing the hepatitis C virus from replicating.
• Zepatier · Merck & Co. · Oncology
  Zepatier works by blocking the NS5A protein of the hepatitis C virus, preventing it from replicating.
• PIBRENTASVIR
• Daklinza · Bristol-Myers Squibb · Oncology
• Elbasvir and Grazoprevir · University Hospital, Toulouse
  ZEPATIER combines elbasvir and grazoprevir to directly act against hepatitis C virus.

Patent intelligence

• hepatitis c virus ns5a inhibitor patent landscape — aggregated cliff calendar, attackable patents, originator estates